{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042506","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.301632+00:00","generated_at":"2026-06-07T22:26:50.822817+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences receives Nasdaq deficiency notice for failing to meet minimum stockholders' equity requirement","bullets":["Stockholders' equity reported $2,435,646 as of Sept 30, 2023, below $2,500,000 minimum.","Company has until Jan 5, 2024 to submit a plan to regain compliance to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Company does not meet alternative quantitative standards for continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042506","json":"https://secwatch.observer/filing/0001493152-23-042506.json","markdown":"https://secwatch.observer/filing/0001493152-23-042506.md","text":"https://secwatch.observer/filing/0001493152-23-042506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223042506/0001493152-23-042506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223042506/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:26:50.822817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bce99e0a7288cab87868f6663a4c66a5713a83b","claim":"Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, reported stockholders’ equity of $2,435,646. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223042506/0001493152-23-042506-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}